<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03123653</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-HBV-01</org_study_id>
    <nct_id>NCT03123653</nct_id>
  </id_info>
  <brief_title>To Study the Efficacy of PEG-IFN Alpha in HBeAg Negative Chronic Hepatitis B Patients After Stopping Nucleotide Analogue Therapy.</brief_title>
  <official_title>To Study the Efficacy of PEG-IFN Alpha in HBeAg Negative Chronic Hepatitis B Patients After Stopping Nucleotide Analogue Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Study population:Person with HBeAg negative CHB on TDF/ETV for more than 1 year

        -  Study design:Prospective,Interventional (single arm study)

        -  Sample size: All the patients fulfilling the inclusion criteria will be included in
           first 6 months and subsequently followed up for 2 years

        -  Intervention: Peg IFN 2b 1.5mcg/kg once every week for 48 weeks

        -  Monitoring and assessment: LFT,HBV DNA and HbsAg at baseline, 4 weeks, 12 weeks,24
           weeks,48 weeks ,72 weeks and 96 weeks, CBC every month and Thyroid function Test every
           3rd month

        -  Adverse effects: The most frequently reported side effects of IFN-based therapy are
           flu-like symptoms, headache, fatigue, myalgia, alopecia, and local reaction at the
           injection site. Peg-IFN have myelosuppressive effects; however, neutropenia\1000/mm3 and
           thrombocytopenia \500,000/ mm3 are not common unless patients already have cirrhosis
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 17, 2017</start_date>
  <completion_date type="Anticipated">September 17, 2020</completion_date>
  <primary_completion_date type="Actual">September 17, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Virological Response-HBV DNA&lt;2000IU/ml after stopping PEG IFN alpha</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Loss of HBsAg after 48 weeks of PEG IFN alpha</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End treatment Response: HBV-DNA -undetectable after 48 weeks of PEG-IFN</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Off treatment Virological response defined as No clinical relapse during 1 year follow up after stopping therapy</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Peg IFN 2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peg IFN 2b 1.5mcg/kg once every week for 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg IFN 2b</intervention_name>
    <description>Peg IFN 2b 1.5mcg/kg once every week for 48 weeks</description>
    <arm_group_label>Peg IFN 2b</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - HBeAg negative Chronic HBV infection who are having HBV DNA-undetectable. ALT &lt;40 IU/ml
        No Advanced fibrosis[LSM &lt;14 KPa] TDF/ETV &gt;1 year Clinical Relapse after stopping NA will
        be defined as HBV DNA&gt;2000IU/ml and ALT &gt; 80IU

        Exclusion Criteria:

        - HBeAg+ CHB Pregnancy Cirrhosis on biopsy or LSM &gt;14 Co-infection- HIV/HCV/HDV
        Immunosuppressive therapy Renal failure S.Bilirubin&gt;2mg/dl Patient having neutropenia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of Liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 19, 2017</study_first_submitted>
  <study_first_submitted_qc>April 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>February 1, 2020</last_update_submitted>
  <last_update_submitted_qc>February 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

